Tactile Medical/$TCMD
1D1W1MYTD1Y5YMAX
Capital at risk
About Tactile Medical
Tactile Systems Technology Inc is a medical technology company. The company is engaged in developing and providing medical devices for the treatment of chronic diseases. The firm's proprietary platform flexitouch system, provides a home-based solution for lymphedema patients. The entire system is another home solution for patients with chronic swelling and actitouch system for chronic venous insufficiency patients that may be worn throughout the day.
- Ticker
- $TCMD
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 1,086
- Headquarters
- Minneapolis, United States
- Website
- tactilemedical.com
Tactile Medical Metrics
BasicAdvanced
$511M
20.89
$1.08
0.82
-
Price and volume
Market cap
$511M
Beta
0.82
52-week high
$37.77
52-week low
$13.37
Average daily volume
355K
Financial strength
Current ratio
4.12
Quick ratio
3.368
Long term debt to equity
0.05
Total debt to equity
0.064
Interest coverage (TTM)
139.56%
Profitability
EBITDA (TTM)
41.738
Gross margin (TTM)
76.78%
Net profit margin (TTM)
7.10%
Operating margin (TTM)
10.00%
Effective tax rate (TTM)
33.44%
Revenue per employee (TTM)
$320,000
Management effectiveness
Return on assets (TTM)
7.92%
Return on equity (TTM)
11.88%
Valuation
Price to earnings (TTM)
20.885
Price to revenue (TTM)
1.449
Price to book
2.29
Price to tangible book (TTM)
3.67
Price to free cash flow (TTM)
21.441
Free cash flow yield (TTM)
4.66%
Free cash flow per share (TTM)
1.053
Growth
Revenue change (TTM)
17.22%
Earnings per share change (TTM)
72.86%
3-year revenue growth (CAGR)
9.56%
10-year revenue growth (CAGR)
17.24%
3-year earnings per share growth (CAGR)
328.45%
10-year earnings per share growth (CAGR)
33.09%
What the Analysts think about Tactile Medical
Analyst ratings (Buy, Hold, Sell) for Tactile Medical stock.
Analyst projections of the future price of Tactile Medical stock.
Bulls say / Bears say
Q2 2026 revenue rose 7.8% year-over-year to $85.7 million, beating analyst expectations and demonstrating resilient demand across its core treatment platforms. (Reuters)
Gross margin expanded to 76.5% in Q1 2026 from 74% a year earlier, reflecting effective cost management and improved operational leverage. (Reuters)
Tactile Medical secured an exclusive U.S. distribution agreement with ElastiMed for its MyoSleeve wearable compression device to VA and DoD patients, significantly broadening its addressable market. (Reuters)
Net loss of $1.8 million in Q1 2026 underscores quarter-to-quarter volatility and elevated operating expenses despite top-line growth. (SEC)
Management trimmed the upper bound of its 2026 revenue guidance to $366 million from $368 million, signaling a cautious outlook amid uncertainty in airway clearance demand. (SEC)
Airway clearance product sales declined 7% year-over-year in Q2 2026 due to temporary inventory management dynamics among DME providers, indicating potential weakness in that segment. (GlobeNewswire)
Data summarised monthly by Lightyear AI. Last updated on 7 Sept 2026.
Tactile Medical Financial Performance
Revenues and expenses
Tactile Medical Earnings Performance
Company profitability
Upcoming events
No upcoming events
Tactile Medical News
AllArticlesVideos
Funds containing Tactile Medical
Fund name | Fund size | $TCMD weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.02% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.